{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:54:02Z","timestamp":1793724842987,"version":"4.6.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R50CA293523"],"award-info":[{"award-number":["1R50CA293523"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) carries high mortality despite neoadjuvant chemotherapy (NAC) and surgical resection, creating an urgent need for prognostic biomarkers to guide treatment. We aimed to determine whether circulating tumor DNA (ctDNA) detected by next-generation sequencing (NGS) predicts survival in patients with localized PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with localized PDAC were prospectively enrolled at an academic institution between October 2020 and November 2024 (NCT04616131). Patients underwent next-generation sequencing (NGS), with blood samples collected at diagnosis, post-NAC, and post-resection. Total,\n                      <jats:italic>KRAS<\/jats:italic>\n                      -specific, and\n                      <jats:italic>TP53<\/jats:italic>\n                      -specific ctDNA detection rates were quantified. Associations with overall survival (OS) were evaluated by using Kaplan\u2013Meier curves and multivariable Cox proportional hazards models adjusting for key clinical covariates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We collected 219 samples from 113 patients across three treatment timepoints. Mutant\n                      <jats:italic>KRAS<\/jats:italic>\n                      ctDNA was detected in 19% at diagnosis, decreased to 4.6% after NAC (19% vs. 4.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.010), and was detected in 8.2% after resection. Total ctDNA detection at diagnosis predicted lower odds of proceeding to resection (adjusted odds ratio [aOR] 0.38, 95% confidence interval [CI] 0.14\u20130.97,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.049).\n                      <jats:italic>KRAS<\/jats:italic>\n                      and\n                      <jats:italic>TP53<\/jats:italic>\n                      co-occurrence at diagnosis independently predicted shorter OS (adjusted hazard ratio 5.66, 95% CI 2.43\u201313.18,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Increases in total ctDNA maximum variant allele frequency over treatment also predicted shorter OS (adjusted hazard ratio 1.14, 95% CI 1.01\u20131.28,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a large prospective cohort, tumor-agnostic NGS-based ctDNA detection demonstrated prognostic value in patients with localized PDAC undergoing NAC and surgery. These findings suggest ctDNA can inform treatment monitoring and risk stratification, supporting further evaluation in larger, multi-center studies to guide clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20447-0","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:10:34Z","timestamp":1787757034000},"page":"10138-10149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Krishay","family":"Sridalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Vitello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Masnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhavan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine K.","family":"Machhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvetha","family":"Rengaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Chibucos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Janczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Dawravoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Bentrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-6873","authenticated-orcid":false,"given":"Akhil","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"5","key":"20447_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jama.2019.10232","volume":"322","author":"DK Owens","year":"2019","unstructured":"Owens DK, Davidson KW, Krist AH, et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438\u201344. https:\/\/doi.org\/10.1001\/jama.2019.10232.","journal-title":"JAMA."},{"issue":"11s","key":"20447_CR2","doi-asserted-by":"publisher","first-page":"S560","DOI":"10.1016\/j.jacr.2017.08.050","volume":"14","author":"A Qayyum","year":"2017","unstructured":"Qayyum A, Tamm EP, Kamel IR, et al. ACR Appropriateness Criteria(\u00ae) Staging of Pancreatic Ductal Adenocarcinoma. J Am Coll Radiol. 2017;14(11s):S560\u20139. https:\/\/doi.org\/10.1016\/j.jacr.2017.08.050.","journal-title":"J Am Coll Radiol."},{"issue":"5","key":"20447_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/sla.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;267(5):936\u201345. https:\/\/doi.org\/10.1097\/sla.0000000000002234.","journal-title":"Ann Surg."},{"issue":"5","key":"20447_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20(5):318\u201337. https:\/\/doi.org\/10.1038\/s41571-023-00746-1.","journal-title":"Nat Rev Clin Oncol."},{"key":"20447_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2020.00041","volume":"10","author":"QP Janssen","year":"2020","unstructured":"Janssen QP, O\u2019Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Front Oncol. 2020;10:41. https:\/\/doi.org\/10.3389\/fonc.2020.00041.","journal-title":"Front Oncol."},{"issue":"1","key":"20447_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2018.12.002","volume":"46","author":"AG Raufi","year":"2019","unstructured":"Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant Treatment for Pancreatic Cancer. Semin Oncol. 2019;46(1):19\u201327. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.12.002.","journal-title":"Semin Oncol."},{"key":"20447_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2021.05.033","volume":"154","author":"HMH Diab","year":"2021","unstructured":"Diab HMH, Smith HG, Jensen KK, J\u00f8rgensen LN. The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review. Eur J Cancer. 2021;154:73\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.033.","journal-title":"Eur J Cancer."},{"issue":"2","key":"20447_CR8","doi-asserted-by":"publisher","first-page":"188409","DOI":"10.1016\/j.bbcan.2020.188409","volume":"1875","author":"G Luo","year":"2021","unstructured":"Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188409. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188409.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"8","key":"20447_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/cncr.31251","volume":"124","author":"AM Amer","year":"2018","unstructured":"Amer AM, Zaid M, Chaudhury B, et al. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018;124(8):1701\u20139. https:\/\/doi.org\/10.1002\/cncr.31251.","journal-title":"Cancer."},{"issue":"1","key":"20447_CR10","doi-asserted-by":"publisher","first-page":"16211","DOI":"10.1038\/s41598-020-73242-6","volume":"10","author":"FA Vuijk","year":"2020","unstructured":"Vuijk FA, de Muynck L, Franken LC, et al. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci Rep. 2020;10(1):16211. https:\/\/doi.org\/10.1038\/s41598-020-73242-6.","journal-title":"Sci Rep."},{"key":"20447_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci154941","author":"DK Dang","year":"2022","unstructured":"Dang DK, Park BH. Circulating tumor DNA: Current challenges for clinical utility. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci154941.","journal-title":"J Clin Invest."},{"issue":"24","key":"20447_CR12","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/jco.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla M, Loree JM, Kasi PM, Parikh AR. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. J Clin Oncol. 2022;40(24):2846\u201357. https:\/\/doi.org\/10.1200\/jco.21.02615.","journal-title":"J Clin Oncol."},{"key":"20447_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169006","author":"MD Shields","year":"2022","unstructured":"Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23169006.","journal-title":"Int J Mol Sci."},{"key":"20447_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006562","author":"DJ Vitello","year":"2024","unstructured":"Vitello DJ, Shah D, Wells A, et al. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/sla.0000000000006562.","journal-title":"Ann Surg."},{"issue":"12","key":"20447_CR15","doi-asserted-by":"publisher","first-page":"e0227366","DOI":"10.1371\/journal.pone.0227366","volume":"14","author":"F Watanabe","year":"2019","unstructured":"Watanabe F, Suzuki K, Tamaki S, et al. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS One. 2019;14(12):e0227366. https:\/\/doi.org\/10.1371\/journal.pone.0227366.","journal-title":"PLoS One."},{"issue":"7","key":"20447_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.Ccr-22-3526","volume":"29","author":"M Lapin","year":"2023","unstructured":"Lapin M, Edland KH, Tjensvoll K, et al. Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer. Clin Cancer Res. 2023;29(7):1267\u201378. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3526.","journal-title":"Clin Cancer Res."},{"issue":"16","key":"20447_CR17","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.Ccr-19-0197","volume":"25","author":"VP Groot","year":"2019","unstructured":"Groot VP, Mosier S, Javed AA, et al. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clin Cancer Res. 2019;25(16):4973\u201384. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0197.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"20447_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz D, Wang-Renault S, Taieb J, et al. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Br J Cancer. 2022;126(3):440\u20138. https:\/\/doi.org\/10.1038\/s41416-021-01624-2.","journal-title":"Br J Cancer."},{"key":"20447_CR19","doi-asserted-by":"publisher","first-page":"794009","DOI":"10.3389\/fonc.2021.794009","volume":"11","author":"G Botrus","year":"2021","unstructured":"Botrus G, Uson Junior PLS, Raman P, et al. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol. 2021;11:794009. https:\/\/doi.org\/10.3389\/fonc.2021.794009.","journal-title":"Front Oncol."},{"key":"20447_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050994","author":"M Huerta","year":"2021","unstructured":"Huerta M, Rosell\u00f3 S, Sabater L, et al. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13050994.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"20447_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/clinchem\/hvac153","volume":"68","author":"JS Lee","year":"2022","unstructured":"Lee JS, Han Y, Yun WG, et al. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study. Clin Chem. 2022;68(12):1509\u201318. https:\/\/doi.org\/10.1093\/clinchem\/hvac153.","journal-title":"Clin Chem."},{"issue":"1","key":"20447_CR22","doi-asserted-by":"publisher","first-page":"16203","DOI":"10.1038\/s41598-024-67235-y","volume":"14","author":"I Labiano","year":"2024","unstructured":"Labiano I, Huerta AE, Alsina M, et al. Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma. Sci Rep. 2024;14(1):16203. https:\/\/doi.org\/10.1038\/s41598-024-67235-y.","journal-title":"Sci Rep."},{"key":"20447_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006209","author":"D Shah","year":"2024","unstructured":"Shah D, Wells A, Cox M, et al. Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/sla.0000000000006209.","journal-title":"Ann Surg."},{"issue":"9596","key":"20447_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(07)61602-x","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(07)61602-x.","journal-title":"Lancet."},{"issue":"1","key":"20447_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","volume":"5","author":"JD Finkle","year":"2021","unstructured":"Finkle JD, Boulos H, Driessen TM, et al. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021;5(1):63. https:\/\/doi.org\/10.1038\/s41698-021-00202-2.","journal-title":"NPJ Precis Oncol."},{"key":"20447_CR26","unstructured":"Predicine. PredicineCARE\u2122: CLIA validated cfDNA NGS assay for pan-cancer therapy selection and monitoring. 2025. https:\/\/www.predicine.com"},{"issue":"2","key":"20447_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10549-021-06370-w","volume":"190","author":"X Liu","year":"2021","unstructured":"Liu X, Davis AA, Xie F, et al. Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. Breast Cancer Res Treat. 2021;190(2):213\u201326. https:\/\/doi.org\/10.1007\/s10549-021-06370-w.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"20447_CR28","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1038\/s41467-024-51271-3","volume":"15","author":"H Singh","year":"2024","unstructured":"Singh H, Lowder KE, Kapner K, et al. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma. Nat Commun. 2024;15(1):6833. https:\/\/doi.org\/10.1038\/s41467-024-51271-3.","journal-title":"Nat Commun."},{"issue":"10","key":"20447_CR29","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.ajpath.2022.07.007","volume":"192","author":"J Bredno","year":"2022","unstructured":"Bredno J, Venn O, Chen X, Freese P, Ofman JJ. Circulating Tumor DNA Allele Fraction: A Candidate Biological Signal for Multicancer Early Detection Tests to Assess the Clinical Significance of Cancers. Am J Pathol. 2022;192(10):1368\u201378. https:\/\/doi.org\/10.1016\/j.ajpath.2022.07.007.","journal-title":"Am J Pathol."},{"issue":"420","key":"20447_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/01621459.1992.10476282","volume":"87","author":"RJA Little","year":"1992","unstructured":"Little RJA. Regression with Missing X\u2019s: A review. J Am Stat Assoc. 1992;87(420):1227\u201337. https:\/\/doi.org\/10.1080\/01621459.1992.10476282.","journal-title":"J Am Stat Assoc."},{"issue":"7540","key":"20447_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501. https:\/\/doi.org\/10.1038\/nature14169.","journal-title":"Nature."},{"key":"20447_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262210908","author":"D Cho","year":"2025","unstructured":"Cho D, Shin K, Hong TH, et al. Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms262210908.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"20447_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12885-022-09387-6","volume":"22","author":"L Sivapalan","year":"2022","unstructured":"Sivapalan L, Thorn GJ, Gadaleta E, Kocher HM, Ross-Adams H, Chelala C. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer. BMC Cancer. 2022;22(1):369. https:\/\/doi.org\/10.1186\/s12885-022-09387-6.","journal-title":"BMC Cancer."},{"issue":"20","key":"20447_CR34","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.Ccr-14-3215","volume":"21","author":"LL Siu","year":"2015","unstructured":"Siu LL, Conley BA, Boerner S, LoRusso PM. Next-Generation Sequencing to Guide Clinical Trials. Clin Cancer Res. 2015;21(20):4536\u201344. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-3215.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"20447_CR35","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.21873\/anticanres.17836","volume":"45","author":"YK Cheon","year":"2025","unstructured":"Cheon YK, Lee SH, Kim DW, et al. Clearance of TP53 Mutations in ctDNA Reflects Therapeutic Response in Advanced Pancreatic Cancer Patients. Anticancer Res. 2025;45(11):4891\u2013907. https:\/\/doi.org\/10.21873\/anticanres.17836.","journal-title":"Anticancer Res."},{"issue":"3","key":"20447_CR36","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1245\/s10434-021-10985-0","volume":"29","author":"Y Kitahata","year":"2022","unstructured":"Kitahata Y, Kawai M, Hirono S, et al. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy. Ann Surg Oncol. 2022;29(3):1596\u2013605. https:\/\/doi.org\/10.1245\/s10434-021-10985-0.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"20447_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41416-019-0704-2","volume":"122","author":"S Guo","year":"2020","unstructured":"Guo S, Shi X, Shen J, et al. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Br J Cancer. 2020;122(6):857\u201367. https:\/\/doi.org\/10.1038\/s41416-019-0704-2.","journal-title":"Br J Cancer."},{"issue":"9","key":"20447_CR38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","volume":"30","author":"B Lee","year":"2019","unstructured":"Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30(9):1472\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz200.","journal-title":"Ann Oncol."},{"key":"20447_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911521","author":"K Watanabe","year":"2022","unstructured":"Watanabe K, Nakamura T, Kimura Y, et al. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911521.","journal-title":"Int J Mol Sci."},{"issue":"8","key":"20447_CR40","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2024.1575","volume":"10","author":"M Cecchini","year":"2024","unstructured":"Cecchini M, Salem RR, Robert M, et al. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2024;10(8):1027\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1575.","journal-title":"JAMA Oncol."},{"issue":"1","key":"20447_CR41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cas.14245","volume":"111","author":"M Sugimori","year":"2020","unstructured":"Sugimori M, Sugimori K, Tsuchiya H, et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci. 2020;111(1):266\u201378. https:\/\/doi.org\/10.1111\/cas.14245.","journal-title":"Cancer Sci."},{"issue":"1","key":"20447_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/1878-0261.13344","volume":"17","author":"M Amrutkar","year":"2023","unstructured":"Amrutkar M, Verbeke CS, Finstadsveen AV, Dorg L, Labori KJ, Gladhaug IP. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. Mol Oncol. 2023;17(1):59\u201381. https:\/\/doi.org\/10.1002\/1878-0261.13344.","journal-title":"Mol Oncol."},{"issue":"34","key":"20447_CR43","doi-asserted-by":"publisher","first-page":"36894","DOI":"10.18632\/oncotarget.5050","volume":"6","author":"X Zhou","year":"2015","unstructured":"Zhou X, Zhang J, Yun H, et al. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget. 2015;6(34):36894\u2013902. https:\/\/doi.org\/10.18632\/oncotarget.5050.","journal-title":"Oncotarget."},{"issue":"7","key":"20447_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.48","volume":"6","author":"K Trumpi","year":"2017","unstructured":"Trumpi K, Ubink I, Trinh A, et al. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. Oncogenesis. 2017;6(7):e357. https:\/\/doi.org\/10.1038\/oncsis.2017.48.","journal-title":"Oncogenesis."},{"issue":"32","key":"20447_CR45","doi-asserted-by":"publisher","first-page":"109383","DOI":"10.3748\/wjg.v31.i32.109383","volume":"31","author":"T Murakami","year":"2025","unstructured":"Murakami T, Imamura M, Kimura Y, et al. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. World J Gastroenterol. 2025;31(32):109383. https:\/\/doi.org\/10.3748\/wjg.v31.i32.109383.","journal-title":"World J Gastroenterol."},{"issue":"6","key":"20447_CR46","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.pan.2022.06.009","volume":"22","author":"BE Ueberroth","year":"2022","unstructured":"Ueberroth BE, Jones JC, Bekaii-Saab TS. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Pancreatology. 2022;22(6):741\u20138. https:\/\/doi.org\/10.1016\/j.pan.2022.06.009.","journal-title":"Pancreatology."},{"key":"20447_CR47","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3389\/fonc.2020.01220","volume":"10","author":"J Jiang","year":"2020","unstructured":"Jiang J, Ye S, Xu Y, et al. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Front Oncol. 2020;10:1220. https:\/\/doi.org\/10.3389\/fonc.2020.01220.","journal-title":"Front Oncol."},{"key":"20447_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050042","author":"J Cicenas","year":"2017","unstructured":"Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers (Basel). 2017. https:\/\/doi.org\/10.3390\/cancers9050042.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"20447_CR49","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jmoldx.2020.02.010","volume":"22","author":"A Macgregor-Das","year":"2020","unstructured":"Macgregor-Das A, Yu J, Tamura K, et al. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. J Mol Diagn. 2020;22(6):748\u201356. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.02.010.","journal-title":"J Mol Diagn."},{"issue":"1","key":"20447_CR50","doi-asserted-by":"publisher","first-page":"15744","DOI":"10.1038\/s41598-024-65562-8","volume":"14","author":"T Theparee","year":"2024","unstructured":"Theparee T, Akroush M, Sabatini LM, et al. Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations. Sci Rep. 2024;14(1):15744. https:\/\/doi.org\/10.1038\/s41598-024-65562-8.","journal-title":"Sci Rep."},{"issue":"1","key":"20447_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/bjs\/znac354","volume":"110","author":"ZJ Brown","year":"2022","unstructured":"Brown ZJ, Heh V, Labiner HE, et al. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Br J Surg. 2022;110(1):34\u201342. https:\/\/doi.org\/10.1093\/bjs\/znac354.","journal-title":"Br J Surg."},{"issue":"1","key":"20447_CR52","doi-asserted-by":"publisher","first-page":"16971","DOI":"10.1038\/s41598-019-53271-6","volume":"9","author":"JS Lee","year":"2019","unstructured":"Lee JS, Rhee TM, Pietrasz D, et al. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Sci Rep. 2019;9(1):16971. https:\/\/doi.org\/10.1038\/s41598-019-53271-6.","journal-title":"Sci Rep."},{"issue":"6","key":"20447_CR53","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1245\/s10434-020-09278-9","volume":"28","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Uemura K, Murakami Y, et al. Clinical implications of pre- and postoperative circulating tumor DNA in patients with resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2021;28(6):3135\u201344. https:\/\/doi.org\/10.1245\/s10434-020-09278-9.","journal-title":"Ann Surg Oncol."},{"key":"20447_CR54","doi-asserted-by":"publisher","first-page":"102604","DOI":"10.1016\/j.ctrv.2023.102604","volume":"120","author":"L Vidal","year":"2023","unstructured":"Vidal L, Pando E, Blanco L, et al. Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis. Cancer Treat Rev. 2023;120:102604. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102604.","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"20447_CR55","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/sla.0000000000002600","volume":"269","author":"T Michelakos","year":"2019","unstructured":"Michelakos T, Pergolini I, Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733\u201340. https:\/\/doi.org\/10.1097\/sla.0000000000002600.","journal-title":"Ann Surg."},{"issue":"9","key":"20447_CR56","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1245\/s10434-024-15579-0","volume":"31","author":"PN Miller","year":"2024","unstructured":"Miller PN, Romero-Hernandez F, Calthorpe L, et al. Long-Duration Neoadjuvant Therapy with FOLFIRINOX yields favorable outcomes for patients who undergo surgery for pancreatic cancer. Ann Surg Oncol. 2024;31(9):6147\u201356. https:\/\/doi.org\/10.1245\/s10434-024-15579-0.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"20447_CR57","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ejso.2021.11.138","volume":"48","author":"P Kirchweger","year":"2022","unstructured":"Kirchweger P, Kupferthaler A, Burghofer J, et al. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur J Surg Oncol. 2022;48(5):1046\u201353. https:\/\/doi.org\/10.1016\/j.ejso.2021.11.138.","journal-title":"Eur J Surg Oncol."},{"key":"20447_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010004","author":"S Yamamoto","year":"2018","unstructured":"Yamamoto S, Iwakuma T. Regulators of oncogenic mutant TP53 gain of function. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers11010004.","journal-title":"Cancers (Basel)."},{"key":"20447_CR59","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018. https:\/\/doi.org\/10.1101\/cshperspect.a031435.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"20447_CR60","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA."},{"issue":"12","key":"20447_CR61","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","volume":"8","author":"MG Krebs","year":"2022","unstructured":"Krebs MG, Malapelle U, Andr\u00e9 F, et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol. 2022;8(12):1830\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4457.","journal-title":"JAMA Oncol."},{"key":"20447_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.006","author":"J Feng","year":"2025","unstructured":"Feng J, Xiao X, Xia X, et al. A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.006.","journal-title":"Cancer Cell."},{"issue":"4","key":"20447_CR63","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.Ccr-23-2098","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei D, Wang L, Zuo X, Maitra A, Bresalier RS. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2024;30(4):655\u201362. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2098.","journal-title":"Clin Cancer Res."},{"key":"20447_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/jci191939","author":"K Drizyte-Miller","year":"2025","unstructured":"Drizyte-Miller K, Talabi T, Somasundaram A, Cox AD, Der CJ. KRAS: the Achilles\u2019 heel of pancreas cancer biology. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/jci191939.","journal-title":"J Clin Invest."},{"issue":"1","key":"20447_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388(1):33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470.","journal-title":"N Engl J Med."},{"issue":"4","key":"20447_CR66","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10637-023-01380-5","volume":"41","author":"I Mohammed","year":"2023","unstructured":"Mohammed I, Alhammer AH, Arif IS. The p53 reactivator PRIMA-1(MET) synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells. Invest New Drugs. 2023;41(4):587\u201395. https:\/\/doi.org\/10.1007\/s10637-023-01380-5.","journal-title":"Invest New Drugs."},{"issue":"2","key":"20447_CR67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3978\/j.issn.2078-6891.2011.021","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19\u20139 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105\u201319. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2011.021.","journal-title":"J Gastrointest Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20447-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:23:41Z","timestamp":1792207421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20447"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20447-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Northwestern University Institutional Review Board on June 7, 2024 (NMHC IRB #21-012). All procedures were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from all participants prior to enrollment.","order":4,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Ethics"}}]}}